Sarthak Metals

- The company plans a total capex of INR 100 crores over the next 3-5 years for expansion and diversification. - Phase one involves an initial capex of INR 30 crores, to be deployed in stages, timeframe for completion is to be communicated later. - Capex will fund growth in core business facilities and the biotechnology division, including a GMP-grade facility. - Biotechnology capex is aimed to build a technology-driven division with potential peak revenue of around INR 350 crores and 30% gross margins. - Current free cash flow of INR 30 crores is sufficient for initial investments, with further funding details to be provided. - Expansion will include increasing flux cored wire SKUs (two or more in the short term, targeting 8-10 products long-term). - Strategic focus on diversification to mitigate cyclical risks of the core steel consumables business.

- Cored wire business: Target to cross INR 25 crore turnover in the next two years; quarterly revenue around INR 40 crore expected to be sustained. - Biotechnology division: Potential to generate INR 40-50 crore turnover in two years; long-term vision to expand product portfolio to 8-10 SKUs. - Overall revenue mix from biotechnology is currently uncertain due to early stage; could outpace core business growth if successful. - Capex plans: INR 30 crore phase one investment underway with a total planned capex of INR 100 crore over 3-5 years to support growth. - Market conditions: Core business cyclical and impacted by global uncertainties; flux cored wire margins expected to improve to 5-6% from current 3-4%. - No immediate new core business products; focus on diversification and resilience through biotechnology and new product lines.

- Core business (cored wires) has cyclical nature; exact growth projection over next two years is difficult due to global uncertainties. - Target to cross INR 25 crores turnover from flux cored wire business in next two years. - Biotechnology segment holds potential for INR 40-50 crores turnover in two years, but revenue contribution is still uncertain. - Margins for cored wires expected to improve to around 5%-6% in current financial year, up from current 3%-4%. - Company plans phased capex investment of INR 100 crores over 3-5 years, with initial phase INR 30 crores to boost capacities. - Biotechnology business aimed to achieve ~30% gross margins and longer-term significant contribution to profitability. - Overall, diversification into biotech expected to provide insulation from cyclical metal business fluctuations and drive sustained growth.

The transcript provided does not contain specific details regarding the current or expected order book or pending orders for Sarthak Metals Limited. The discussion focuses on financial performance, business segments, diversification into biotechnology, and market outlooks but does not explicitly mention order book status or pending orders. For precise information on the company's order book or pending orders, it is recommended to refer directly to the company's official disclosures or contact their investor relations.

- The company has a healthy balance sheet with INR30 crores of free cash flow, sufficient to comfortably start and fuel growth without immediate fundraising needs. - For the planned capex of INR100 crores (biotechnology and core business expansion), the investment will be done in phases over three to five years. - The initial phase involves an investment of INR30 crores; however, the exact timeline and funding details for this phase are yet to be clarified. - There is no explicit mention of plans for new fundraising through debt or equity in the immediate future. - The company appears to prefer phased capex funded through internal accruals or cash flow, but may update investors as plans become clearer.